PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
68.12
P/E of 68.12 versus zero earnings in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify earnings quality.
669.56
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.45. Jim Chanos would check for potential multiple compression risks.
14.11
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.71. Jim Chanos would check for potential asset write-down risks.
-148.99
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -15.51. Seth Klarman would investigate cash flow improvement potential.
-1078.09
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is -4.01. Seth Klarman would investigate operational improvement potential.
14.11
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.72. Jim Chanos would check for valuation bubble risks.
0.37%
Positive earnings while Drug Manufacturers - Specialty & Generic median shows losses. Peter Lynch would examine earnings quality advantage.
-0.67%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.20%. Seth Klarman would investigate cash flow improvement potential.